Intangible Assets and Goodwill (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Y	Jun. 30, 2011	Dec. 31, 2011 Y
Intangible Assets and Goodwill
Amortization period related to non-IPR&D intangible assets, minimum (in years)			1
Amortization period related to non-IPR&D intangible assets, maximum (in years)			17
Amortizable intangible assets
Gross Carrying Value	$ 2,624,959,000		$ 2,624,959,000		$ 2,293,384,000
Accumulated Amortization	(769,257,000)		(769,257,000)		(682,686,000)
Intangible Assets, Net	1,855,702,000		1,855,702,000		1,610,698,000
Weighted Average Life (in years)			11.3		11.9
Total intangible assets
Gross Carrying Value	4,035,207,000		4,035,207,000		3,527,384,000
Intangible Assets, Net	3,265,950,000		3,265,950,000		2,844,698,000
Increase in gross carrying value of acquired IPR&D product rights from Avila Therapeutics, Inc.			198,400,000
Reduction of contingent consideration liability			25,638,000	(111,169,000)
Amortization expense	44,600,000	70,300,000	86,600,000	139,700,000
Amortization of intangible assets for the next five years			86,568,000	140,249,000
Summary of changes in carrying value of goodwill
Balance at the beginning			1,887,220,000
Acquisition of Avila			153,989,000
Balance at the end	2,040,780,000		2,040,780,000		1,887,220,000
Minimum
Total intangible assets
Amortization of intangible assets for the next five years			180,000,000
Maximum
Total intangible assets
Amortization of intangible assets for the next five years			202,000,000
Gloucester Pharmaceuticals, Inc.
Total intangible assets
Reduction of contingent consideration liability			47,000,000
Acquired developed product rights
Amortizable intangible assets
Gross Carrying Value	2,186,000,000		2,186,000,000		2,186,000,000
Accumulated Amortization	(732,803,000)		(732,803,000)		(666,142,000)
Intangible Assets, Net	1,453,197,000		1,453,197,000		1,519,858,000
Weighted Average Life (in years)			11.9		11.9
Summary of changes in carrying value of goodwill
Tax benefit on the exercise of Pharmion converted stock options					(429,000)
Technology
Amortizable intangible assets
Gross Carrying Value	333,333,000		333,333,000		2,534,000
Accumulated Amortization	(16,069,000)		(16,069,000)		(190,000)
Intangible Assets, Net	317,264,000		317,264,000		2,344,000
Weighted Average Life (in years)			7.0		10.0
Summary of changes in carrying value of goodwill
Acquisition of Avila			330,800,000
Licenses
Amortizable intangible assets
Gross Carrying Value	64,250,000		64,250,000		64,250,000
Accumulated Amortization	(8,026,000)		(8,026,000)		(6,108,000)
Intangible Assets, Net	56,224,000		56,224,000		58,142,000
Weighted Average Life (in years)			16.8		16.8
Other
Amortizable intangible assets
Gross Carrying Value	41,376,000		41,376,000		40,600,000
Accumulated Amortization	(12,359,000)		(12,359,000)		(10,246,000)
Intangible Assets, Net	29,017,000		29,017,000		30,354,000
Weighted Average Life (in years)			8.8		8.8
Acquired IPR&D product rights
Non-amortized intangible assets:
Carrying Value	1,410,248,000		1,410,248,000		1,234,000,000
Acquired IPR&D product rights | Gloucester Pharmaceuticals, Inc.
Total intangible assets
Impairment charge			$ 22,100,000